PRECISION BIOSCIENCES INC

August 24, 2026 The post Dear Duchenne Community Newsletter: appeared first on Precision BioSciences.

Yuen, MF, et. al. (2026) European Association for the Study of the Liver (EASL) Conference. The post First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV appeared first on Precision BioSciences.

Mischler, Adam. Et al. (2026) The American Society of Gene & Cell Therapy (ASGCT) Conference. The post PBGENE-DMD gene editing drives safe, efficacious, and durable functional improvement in a humanized Duchenne muscular dystrophy mouse model appeared first on Precision BioSciences.

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2 The post Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update appeared first on Precision BioSciences.

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial The post Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 appeared first on Precision BioSciences.

- Arkansas Children's Hospital activated as the first clinical trial site   and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD   - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel The post Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study appeared first on Precision BioSciences.

August 24, 2026 The post Dear Duchenne Community Newsletter: appeared first on Precision BioSciences.

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from The post Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting appeared first on Precision BioSciences.

- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 22, 2026-- Precision BioSciences, Inc. The post Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 appeared first on Precision BioSciences.

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to The post Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries appeared first on Precision BioSciences.